CYTK

CYTK

USD

Cytokinetics Incorporated Common Stock

$61.480+1.180 (1.957%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$60.300

Máximo

$61.480

Mínimo

$60.010

Volume

1.92M

Fundamentos da empresa

Capitalização de mercado

7.5B

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

2.29M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $29.31Atual $61.480Máximo $64.13

Notícias relacionadas

Analyst Upgrades

B. Riley Securities Reiterates Buy on Cytokinetics, Raises Price Target to $90

B. Riley Securities analyst Mayank Mamtani reiterates Cytokinetics with a Buy and raises the price target from $80 to $90.

Ver mais
B. Riley Securities Reiterates Buy on Cytokinetics, Raises Price Target to $90
PR Newswire

Investors in Cytokinetics, Incorporated Should Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights - CYTK

The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of...

Ver mais
Investors in Cytokinetics, Incorporated Should Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights - CYTK
GlobeNewswire

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE

Ver mais
Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
PR Newswire

CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27,...

Ver mais
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
PR Newswire

CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27,...

Ver mais
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
GlobeNewswire

Cytokinetics to Participate in November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor conferences

PR Newswire

Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against...

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.